To The Moon

The property group tackled the concerns in a bourse filing on Thursday (Apr 17) night, ahead of its annual general meeting (AGM) on Apr 23. Describing the group’s share price-to-asset value gap as a “chasm”, a shareholder said it reflected the “profound failure” of CDL’s board to “crystallise value”. CDL’s estimated revalued net asset value (RNAV) stands at S$19.86 per share this giant has to be Revalued towards fair value !! $CityDev(C09.SI)$ $BABA-W(09988)$ $TENCENT(00700)$ $MIXUE GROUP(02097)$ $DBS Group Holdings(D05.SI)$&nb

🌟🌟🌟In the midst of market volatility due to the new policies of the Trump Administration, it is not surprising that Gold is the new paradigm of safety. I am so happy that my investment in $iShares Gold Trust(IAU)$ has been on a upward momentum as a safe haven amid this volatility. @Tiger_comments @TigerStars @CaptainTiger @TigerClub

$NVIDIA(NVDA)$ $Costco(COST)$ 📉 🪤🔥Nvidia’s $60M Put Wall: Crash Signal or Genius Trap? 🔥🪤 $NVDA lit up the options tape on Thursday with a $60M bomb in short-dated, single-leg ask-side puts, stacked sky-high. Is this a crash signal, or the ultimate trap? At $101.27 post-market, Nvidia’s on a knife-edge, while tech traders hold their breath. This isn’t noise, it’s a screaming alert from the institutional playbook. 📉 Puts Are Piling Up, Big Money’s Betting on Pain 📉 Puts: $59.75M, towering bearish bets Calls: $5.31M, barely a murmur Not a tilt, it’s a full-on “brace for impact” signal. 🔑 Key Levels to Watch, Break These and It’s Game Over 🔴 $96.00 is the last stand, cracks here open the door to $92 🟠 $98.00

$SPDR S&P Biotech ETF ( $Spdr S&P Biotech Etf(XBI)$ )$ $Pfizer ( $Pfizer(PFE)$ )$ $S&P 500(. $S&P 500(.SPX)$ )$ $Dow Jones Industrial Average(. $Dow Jones(.DJI)$ )$As of April 18, 2025, the U.S. stock market is reeling from a volatile week, with the S&P 500 shedding 2.8% on April 17 and the Dow Jones Industrial Average dropping 1,200 points in a single session. Fears of escalating trade tensions and a hawkish Federal Reserve have sparked widespread selling. Yet, amid the chaos, biotech stocks are staging an unexpected rally, driven by breakthrough drug approvals and M&A chatter. Is this a sector to

I first took noticed of $Rocket Lab USA, Inc.(RKLB)$ in Q4 2024. After observing from afar, I decided to share a post on Rocket Lab vs SpaceX on 26 Mar 2025. Click here ! for details ! (Since then) like any US listed companies, RKLB has faced significant volatility, especially this month -April 2025. This was largely due to global trade tensions and tariff policies enacted by the Trump administration. As of 17 Apr 2025, RKLB is priced at $19.74, marginally higher (+$0.11) than its Thu, 10 Apr 2025 closing of $19.63 Again, like other US stocks, RKLB is struggling to regain momentum after a -12% decline ea

$NVIDIA(NVDA)$ $Costco(COST)$ 📉 🪤🔥Nvidia’s $60M Put Wall: Crash Signal or Genius Trap? 🔥🪤 $NVDA lit up the options tape on Thursday with a $60M bomb in short-dated, single-leg ask-side puts, stacked sky-high. Is this a crash signal, or the ultimate trap? At $101.27 post-market, Nvidia’s on a knife-edge, while tech traders hold their breath. This isn’t noise, it’s a screaming alert from the institutional playbook. 📉 Puts Are Piling Up, Big Money’s Betting on Pain 📉 Puts: $59.75M, towering bearish bets Calls: $5.31M, barely a murmur Not a tilt, it’s a full-on “brace for impact” signal. 🔑 Key Levels to Watch, Break These and It’s Game Over 🔴 $96.00 is the last stand, cracks here open the door to $92 🟠 $98.00

As per my Thursday post, US market did not rally and close on a high (click here ! for details, Repost to share !). The media said US stocks closed mixed on Thursday, booking weekly losses on the final session of the week. Most media “agreed” that the 2 factors that most affected market sentiments, particularly blue-chip Dow Jones Industrial Average were: Trump’s latest bitch-fit over what Fed chair Jerome Powell had said in his xx speech about overall US economy. Historic drop in $UnitedHealth(UNH)$ after the insurer reported its quarterly earnings and delivered an outlook that disappointed Wall Street.

Healthcare giant $UnitedHealth(UNH)$ obliterated and is on track for its biggest loss in 27 years.Keydata: EPS of $7.20 missing expectations of $7.29, Revenue of $109.6B missing expectations of $111.6B.Why is $UNH down 23%? An amazing buying opportunityQ1 2025 Earnings Report AnalysisCompany OverviewUnitedHealth Group is a globally leading diversified healthcare company, operating primarily through two business segments: UnitedHealthcare (which provides health insurance and benefits services) and Optum (which offers information and technology-supported health services). The company is committed to helping people live healthier lives through innovative healthcare solutions and efficient operating models.Business and Business Model IntroductionUnited

It was roughly about a month ago that Wedbush Securities analyst Dan Ives warned Tesla CEO Elon Musk that patience among his shareholders was “wearing very thin”. It now looks as if it has finally snapped, after Wall Street’s most reliable $Tesla Motors(TSLA)$ bull slashed his price target nearly in half, blaming the polarizing CEO for poisoning the well. Moving forward, Ives said, EV sales for the brand that once hit breakneck speeds will only crawl ahead with percentage gains in the single digit as a result. “Demand destruction for Tesla and brand damage is real,” Ives wrote, “and has morphed into something much more concerning over the past few months.” By cutting his price target to $315 from $550, the Wedbush analyst broke ranks from many Tes

$SPDR S&P Biotech ETF ( $Spdr S&P Biotech Etf(XBI)$ )$ $Pfizer ( $Pfizer(PFE)$ )$ $S&P 500(. $S&P 500(.SPX)$ )$ $Dow Jones Industrial Average(. $Dow Jones(.DJI)$ )$As of April 18, 2025, the U.S. stock market is reeling from a volatile week, with the S&P 500 shedding 2.8% on April 17 and the Dow Jones Industrial Average dropping 1,200 points in a single session. Fears of escalating trade tensions and a hawkish Federal Reserve have sparked widespread selling. Yet, amid the chaos, biotech stocks are staging an unexpected rally, driven by breakthrough drug approvals and M&A chatter. Is this a sector to